An open-label study to evaluate the safety and tolerability of 12 weeks of treatment with oral REN001 in subjects with long-chain fatty acid oxidation disorders (LC-FAOD)

Vockley et al., INFORM 2022

A prospective, multicenter, non-interventional study to investigate the disease characteristics of adult patients with long-chain fatty acid oxidation disorders: The FORWARD study

Gillingham et al., INFORM 2022

REN001, a novel peroxisome proliferator-activated receptor delta (PPARδ)agonist, improves gait in patients with primary mitochondrial myopathy after 12-weeks

Alcock et al., Neuromuscular Medicine, 2022

Characterization of Fatigue in Primary Mitochondrial Myopathy: Findings from a Qualitative Interview Study

Karaa et al., UMDF Mitochondrial Medicine, 2021